AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a participant of Biotechnology, has a market of $206.78M.
The firm has seen its stock move between a high and a low of $41.30% and $290.78%, respectively, over the preceding 12 months.
The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is in the Top 1%. Long term indicators mostly agree with the trend.
Recently, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported that the stock’s performance for the last week is 163.55% and performance recorded this month is 148.41%. For the quarter, though, the shares price has moved 201.39%, compared with stock movement of 236.15% for the half-year period and 104.85% for the year. So far this year stock of AVEO Pharmaceuticals, Inc. have moved 261.11%.
Various analysts have studied the stock of AVEO Pharmaceuticals, Inc., setting average price target of $2.30. That compares with the prevailing price of $1.95. In terms of equity recommendation, the average analysts? call on the stock is 1.50.
AVEO Pharmaceuticals, Inc. stock has average volume and relative volume of 1.54M and 44.19, correspondingly.
The weekly volatility for the stock stands at AVEO Pharmaceuticals, Inc. is 25.74%, while the monthly volatility is 11.52%.
The equity has a short float of 1.83% and short ratio of 1.26. It is a market sentiment indicator providing a hint on whether investors project a stock to rise or fall.
AVEO Pharmaceuticals, Inc. has a current ratio of 2.50 for the recent quarter. Quick ratio for the last quarter period is 2.50. The firm has Total/Debt/Equity ratio of Total Debt/Equity 2.88 and Long Term Debt/Equity ratio 2.16.
AVEO Pharmaceuticals, Inc. has recorded return on equity of -756.50% for the previous 12 months, while return on investment for the equivalent period is -243.80%. It also recorded return on assets of -79.10% for the previous 12 months.
AVEO Oncology last week announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA(TM) (tivozanib) for approval as a treatment for patients with advanced renal cell carcinoma (RCC). The CHMP’s recommendation is now referred to the European Commission (EC). The EC, which typically adheres to the recommendation of the CHMP, but is not obligated to do so, is expected to make its final decision in about 67 days. If approved by the EC, marketing authorization for tivozanib will be granted in all 28 countries of the European Union, Norway, Iceland and Liechtenstein. EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, is the European licensee for tivozanib.